Cannabix Technologies to Participate in Green
Lab Held by Montgomery County Police Department
(Maryland)
Vancouver, British
Columbia, December 22, 2023 -- InvestorsHub NewsWire --
Cannabix
Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix") developer of
marijuana and alcohol breath testing devices reports that
it will be participating
in a "green lab" testing day in Montgomery County, Maryland held by
the Montgomery County Police Department. In particular the Company
will be supplying its marijuana breathalyzer technology and sending
its own representative to facilitate the collection of
breath samples alongside law enforcement officers who are testing
subjects under the influence of marijuana. The green lab is being
held by the Public Safety Training
Academy for the
Montgomery County Police Department. Various local, regional and
out of state representatives are expected to attend the event being
held in early January 2024.
The Montgomery County Police Department has
held green lab events since 2017, in order to help train police
officers about cannabis driving impairment. The green lab aids
officers in Advanced Roadside Impaired
Driving Enforcement training which helps them learn of the
effects of marijuana, and what signs to look for when conducting
sobriety tests. Cannabix will be sending its own representative
and Breath Collection Units ("BCU") (See Figure 1) to
collect breath samples at various time points pre and post
marijuana consumption by subjects. Furthermore, Cannabix will be
introducing its technology as a new tool for detection of marijuana
in breath to attendees.
In recent months, Cannabix
has been using its BCU and Mass Spectrometer Breath Sampler
("MSBS") to quantify delta-9 THC in human breath samples. Cannabix
scientists are using an internal standard to generate a calibration
curve for THC quantification in breath samples. Currently, a limit
of detection and limit of quantification have been achieved with
human subjects in the low picogram range. This allows detection of
THC from smoking and edibles up to 4+ hours after
consumption.
Cannabix will look to
participate in other green labs tests in order to introduce its
products to law enforcement stakeholders and collect important data
with real world testing conditions.
Fig 1. Cannabix
updated Breath Collection Unit (BCU)
About Cannabix
Technologies Inc.
Cannabix Technologies Inc.
is a developer of marijuana and alcohol breathalyzer technologies
for law enforcement, workplaces and laboratories. Cannabix is
working to develop delta-9 THC and alcohol screening devices.
Delta-9 THC is the psychoactive component of marijuana that causes
impairment. Breath testing for delta-9 THC would allow employers
and law enforcement to identify recent marijuana use that
better aligns with impairment. Cannabix is the developer of
contactless breath alcohol detection
devices for employers and other settings.
We seek Safe
Harbor.
On behalf of the
Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies
Inc.
For further information,
contact the Company at info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary
Statement Regarding Forward-Looking Statements
This press
release contains forward-looking information that involves various
risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that its development of
breathalyzer technologies will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. The is no
assurance that the Company will enter into any partnerships to
advance any of its corporate initiatives or technologies. There is
no assurance that any "patent pending" or "provisional patents"
technologies licensed by the Company or owned by the Company will
receive patent status by regulatory authorities. The Company is not
currently selling commercial breathalyzers. Actual results and
future events could differ materially from those anticipated in
such information. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend to update these forward-looking
statements.